{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:54:09Z","timestamp":1787025249606,"version":"build-2736575974"},"reference-count":30,"publisher":"Oceanside Publications Inc.","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["allergy asthma proc"],"published-print":{"date-parts":[[2025,7,1]]},"abstract":"<jats:p>\n                    <jats:bold>Background:<\/jats:bold>\n                    Initial studies recommended that omalizumab be administered by health-care professionals. However, subsequent research revealed that the prevalence of anaphylaxis after subcutaneous omalizumab injections was only 0.09%.\n                    <jats:bold>Objective:<\/jats:bold>\n                    In this study,\n we aimed to evaluate the effects of omalizumab self-administration at home compared with hospital administration on asthma control.\n                    <jats:bold>Method:<\/jats:bold>\n                    Medical records of 45 patients diagnosed with severe atopic asthma, treated with omalizumab in our clinic, and subsequently transitioned\n to self-injection at home after appropriate training were retrospectively reviewed. These patients were monitored regularly for at least 1 year before and after the transition. The asthma control level was assessed by using the Asthma Control Test (ACT).\n                    <jats:bold>Results:<\/jats:bold>\n                    The ACT\n score average 1 year after home use was significantly higher than 1 year before home use (0.047); however, the scores before and after 6 months and 3 months home use were similar. A significant reduction in the number of exacerbations was observed after home medication use (p\u2009=\u20090.050),\n whereas no significant differences were detected in systemic steroid use or emergency admissions. The presence of eosinophilia and comorbidities did not significantly affect periodic ACT values after home use.\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    Our study demonstrated the safety and efficacy of\n omalizumab for home administration in patients with severe atopic asthma, and it should be emphasized that proper patient selection and training are crucial to ensure the safety of home therapy. It is effective in both symptom control and prevention of exacerbations, and the effectiveness\n of home use was not diminished by the presence of comorbidities or eosinophilia compared with hospital use.\n                  <\/jats:p>","DOI":"10.2500\/aap.2025.46.250021","type":"journal-article","created":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:34:02Z","timestamp":1751934842000},"page":"274-279","source":"Crossref","is-referenced-by-count":3,"title":["Omalizumab home injection versus hospital administration in severe asthma: Impact on asthma control"],"prefix":"10.2500","volume":"46","author":[{"given":"Bahar","family":"Arslan","sequence":"first","affiliation":[{"name":"From the Division of Allergy and Clinical Immunology, Department of Chest Diseases, Erciyes University School of Medicine, Kayseri, Turkey;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gulden","family":"Pacaci Cetin","sequence":"additional","affiliation":[{"name":"From the Division of Allergy and Clinical Immunology, Department of Chest Diseases, Erciyes University School of Medicine, Kayseri, Turkey;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serhat","family":"Seker","sequence":"additional","affiliation":[{"name":"From the Division of Allergy and Clinical Immunology, Department of Chest Diseases, Erciyes University School of Medicine, Kayseri, Turkey;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hatice Eylul","family":"Bozkurt Yilmaz","sequence":"additional","affiliation":[{"name":"From the Division of Allergy and Clinical Immunology, Department of Chest Diseases, Erciyes University School of Medicine, Kayseri, Turkey;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elif","family":"Aktas Yapici","sequence":"additional","affiliation":[{"name":"From the Division of Allergy and Clinical Immunology, Department of Chest Diseases, Erciyes University School of Medicine, Kayseri, Turkey;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serpil","family":"Koyluce","sequence":"additional","affiliation":[{"name":"From the Division of Allergy and Clinical Immunology, Department of Chest Diseases, Erciyes University School of Medicine, Kayseri, Turkey;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elif","family":"Acar","sequence":"additional","affiliation":[{"name":"From the Division of Allergy and Clinical Immunology, Department of Chest Diseases, Erciyes University School of Medicine, Kayseri, Turkey;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tugba","family":"Ertugrul","sequence":"additional","affiliation":[{"name":"From the Division of Allergy and Clinical Immunology, Department of Chest Diseases, Erciyes University School of Medicine, Kayseri, Turkey;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murat","family":"Turk","sequence":"additional","affiliation":[{"name":"From the Division of Allergy and Clinical Immunology, Department of Chest Diseases, Erciyes University School of Medicine, Kayseri, Turkey;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Insu","family":"Yilmaz","sequence":"additional","affiliation":[{"name":"From the Division of Allergy and Clinical Immunology, Department of Chest Diseases, Erciyes University School of Medicine, Kayseri, Turkey;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1355","reference":[{"key":"B1","article-title":"Global strategy for asthma management and prevention","year":"2024"},{"key":"B2","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.anai.2018.07.033","article-title":"Selecting the right biologic for your patients with severe asthma","volume":"121","author":"Manka","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B3","doi-asserted-by":"crossref","first-page":"1753466619841350","DOI":"10.1177\/1753466619841350","article-title":"Omalizumab and long-term quality of life outcomes in patients with moderate-to-severe allergic asthma: a systematic review","volume":"13","author":"Colombo","year":"2019","journal-title":"Ther Adv Respir Dis"},{"key":"B4","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.jaci.2011.04.010","article-title":"American Academy of Allergy, Asthma & Immunology\/American College of Allergy, Asthma & Immunology Omalizumab-Associated Anaphylaxis Joint Task Force follow-up report","volume":"128","author":"Cox","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"B5","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1710-1492-6-32","article-title":"Omalizumab: practical considerations regarding the risk of anaphylaxis","volume":"6","author":"Kim","year":"2010","journal-title":"Allergy Asthma Clin Immunol"},{"key":"B6"},{"key":"B7"},{"key":"B8"},{"key":"B9","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.anai.2020.05.029","article-title":"Keeping risk in context while rethinking the setting of asthma biologics in patient-centered care","volume":"125","author":"Greenhawt","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B10","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1185\/03007995.2013.844115","article-title":"Immunogenicity and safety of omalizumab in pre-filled syringes in patients with allergic (IgE-mediated) asthma","volume":"30","author":"Somerville","year":"2014","journal-title":"Curr Med Res Opin"},{"key":"B11","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jaip.2019.09.037","article-title":"Estimation of health and economic benefits of clinic versus home administration of omalizumab and mepolizumab","volume":"8","author":"Shaker","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B12","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1080\/14712598.2021.1882990","article-title":"Self-administration of omalizumab: why not? A literature review and expert opinion","volume":"21","author":"Menzella","year":"2021","journal-title":"Expert Opin Biol Ther"},{"key":"B13","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1164\/rccm.200801-060ST","article-title":"An official American Thoracic Society\/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice","volume":"180","author":"Reddel","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"B14","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1007\/s11136-012-0309-1","article-title":"The validation of the Turkish version of Asthma Control Test","volume":"22","author":"Uysal","year":"2013","journal-title":"Qual Life Res"},{"key":"B15","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1136\/ejhpharm-2019-001914","article-title":"Multicentre experience of home omalizumab treatment for chronic spontaneous urticaria","volume":"27","author":"Denman","year":"2020","journal-title":"Eur J Hosp Pharm"},{"key":"B16","doi-asserted-by":"crossref","first-page":"100725","DOI":"10.1016\/j.waojou.2022.100725","article-title":"The impact of home treatment and self-administration of omalizumab on chronic urticaria","volume":"15","author":"Wiuff","year":"2022","journal-title":"World Allergy Organ J"},{"key":"B17","doi-asserted-by":"crossref","first-page":"100587","DOI":"10.1016\/j.waojou.2021.100587","article-title":"Rapid transition to home omalizumab treatment for chronic spontaneous urticaria during the COVID-19 pandemic: a patient perspective","volume":"14","author":"King","year":"2021","journal-title":"World Allergy Organ J"},{"key":"B18","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1080\/02770900701209749","article-title":"Home therapy with subcutaneous anti-immunoglobulin-E antibody omalizumab in 25 patients with immunoglobulin-E-mediated (allergic) asthma","volume":"44","author":"Liebhaber","year":"2007","journal-title":"J Asthma"},{"key":"B19","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.jaip.2020.11.038","article-title":"The impact of COVID-19 pandemic on adult and pediatric allergy & immunology services in the UK National Health Service","volume":"9","author":"Krishna","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B20","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1136\/archdischild-2020-320626","article-title":"Paediatric severe asthma biologics service: from hospital to home","volume":"106","author":"Makhecha","year":"2021","journal-title":"Arch Dis Child"},{"key":"B21","doi-asserted-by":"crossref","first-page":"675281","DOI":"10.3389\/fped.2021.675281","article-title":"Case report: self-administration of omalizumab in an adolescent with severe asthma during SARS-CoV-2 infection","volume":"9","author":"Paladini","year":"2021","journal-title":"Front Pediatr"},{"key":"B22","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1111\/all.14456","article-title":"COVID-19 in a patient with severe asthma treated with omalizumab","volume":"75","author":"Lommatzsch","year":"2020","journal-title":"Allergy"},{"key":"B23","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.anai.2023.07.017","article-title":"Real-world severe asthma biologic administration and adherence differs by biologic: CHRONICLE study results","volume":"131","author":"Ledford","year":"2023","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B24","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.jaip.2019.07.011","article-title":"Omalizumab treatment patterns among patients with asthma in the US Medicare population","volume":"8","author":"Li","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B25","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.chest.2020.10.050","article-title":"Adherence to asthma biologics: implications for patient selection, step therapy, and outcomes","volume":"159","author":"Maddux","year":"2021","journal-title":"Chest"},{"key":"B26","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/j.jaip.2022.02.020","article-title":"Longitudinal impact of sputum inflammatory phenotypes on small airway dysfunction and disease outcomes in asthma","volume":"10","author":"Abdo","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B27","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1111\/all.15719","article-title":"Trait profiles in difficult-to-treat asthma: clinical impact and response to systematic assessment","volume":"78","author":"Lin","year":"2023","journal-title":"Allergy"},{"key":"B28","first-page":"1","article-title":"Predicting frequent asthma exacerbations using blood eosinophil count and other patient data routinely available in clinical practice","volume":"9","author":"Price","year":"2016","journal-title":"J Asthma Allergy"},{"key":"B29","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s40413-017-0159-y","article-title":"Severe asthma and quality of life","volume":"10","author":"Hossny","year":"2017","journal-title":"World Allergy Organ J"},{"key":"B30","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s40001-023-01097-4","article-title":"The relationship between obstructive sleep apnea and asthma severity and vice versa: a systematic review and meta-analysis","volume":"28","author":"Wang","year":"2023","journal-title":"Eur J Med Res"}],"container-title":["Allergy and Asthma Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/ocean\/aap\/2025\/00000046\/00000004\/art00003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T04:32:52Z","timestamp":1752553972000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.2500\/aap.2025.46.250021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7,1]]}},"alternative-id":["1088-5412(20250701)46:4L.274;1-"],"URL":"https:\/\/doi.org\/10.2500\/aap.2025.46.250021","relation":{},"ISSN":["1088-5412"],"issn-type":[{"value":"1088-5412","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7,1]]}}}